On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

ASML extends losses after cutting sales guidance, Nvidia stock edges higher, and third-quarter earnings at Morgan Stanley top ...

Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Fintel reports that on October 16, 2024, HC Wainwright & Co. upgraded their outlook for NovoCure (NasdaqGS:NVCR) from Neutral ...

NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Novocure (NVCR) shares rise 6% after FDA approval for Optune Lua in treating metastatic non-small cell lung cancer.

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.